Leukemia Clinical Trials

Showing 6041-6060 of 10,987 trials

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

NCT03263637

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of AZD4573 in subjects with relapsed or refractory haematological malignancies.

Relapsed or Refractory Haematological Malignancies IncludingAcute Myeloid LeukemiaAcute Lymphocytic Leukemia+8 more

AstraZeneca44 participantsStarted Oct 2017

Aachen, Germany • Bonn, Germany • Göttingen, Germany +9 more locations

UNKNOWNPhase 2

Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma

NCT05087602

Evaluate PFS of PD-1 Toripalimab Combined With Anlotinib in Subjects With unresectable locally advanced or metastatic acral malignant melanoma

Locally Advanced or Metastatic Acral Malignant Melanoma

Qilu Hospital of Shandong University29 participantsStarted Nov 2021

Jinan, Shandong, China

COMPLETEDEARLY Phase 1

UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients

NCT03158883

This is a pilot, single center, open-label study to examine the ORR, safety, and toxicity of avelumab in combination with SAR in non-responding and progressing NSCLC patients previously treated with a PD-1 Inhibitor.

Metastatic Non-small Cell Lung Cancer (NSCLC)

Megan Daly, MD8 participantsStarted May 2017

Sacramento, California, United States

Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies

Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma

UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients

Related Searches

ADNEXMR Scoring System: Impact of an MR Scoring System on Therapeutic Strategy of Pelvic Adnexal Masses

Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Virtual Visitation in Intensive Care Unit Study

Study of AMV564 in Subjects With Advanced Solid Tumors

The Prevalence of Contact Allergies for Wound Dressings In Patients With Diabetic Foot Ulcers (PAID Study)

Myeloid Mutations Register in R/R CML

Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer

Effects of Probiotic VSL#3 on Expression of Small Intestinal Renin-angiotensin System

Gut Microbiome and Its Immune Modulation in Locally Advanced Rectal Cancer

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia

HCT Versus CT in Elderly AML

Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)

Study of AMV564 in Patients With AML

A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL